DOJ launches investigation into McKinsey’s past work for opioid manufacturers; Spending on GLP-1 drugs balloons; UnitedHealth Group is shutting down Optum’s virtual care business.
Five things for pharma marketers to know for Wednesday morning
The Supreme Court is slated to hear a case about the Emergency Medical Treatment and Labor Act; Xaira Therapeutics launches with the goal of using AI to transform drug R&D; Flonase forges a Bridgerton connection for its ‘Polin’ ad campaign.
Five things for pharma marketers to know for Tuesday morning
Cardinal Health loses a major contract with OptumRx; The Supreme Court declines to hear a bid by Vanda Pharmaceuticals to revive patents for its sleep-disorder drug Hetlioz; Ogilvy-backed campaign asks if men have the balls to take a pregnancy test for testicular cancer.
Five things for pharma marketers to know for Thursday morning
Eli Lilly’s Mounjaro has limited availability through February; Samsung Biologics says its net profit fell 21.4% in Q4 2023 due largely to a one-off factor; The FDA denies approval for a newer formulation of tesamorelin that Theratechnologies proposed.
Five things for pharma marketers to know for Monday morning
Will Bernie Sanders subpoena Big Pharma execs?; Drugmakers raise the list prices for Ozempic and Mounjaro; Scientists identify a persistent change in a handful of blood proteins in people with long COVID.
Five things for pharma marketers to know on Tuesday morning
Novartis in talks to buy Cytokinetics; Boston Scientific acquires medtech company Axonics in $3.7 billion deal; Lilly’s Zepbound obesity drug reaches 25,000 new prescriptions mark.
Five things for pharma marketers to know on Tuesday
Medical complications rise at hospitals bought by PE firms; BMS snaps up radiation cancer therapy firm; Government ban on certain Apple Watches kicks in.